AI
IBB icon

Accredited Investors’s iShares Biotechnology ETF IBB Stock Holding History

Accredited Investors’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$461K Buy
+2,426
New +$417K 0.02% 185

Other funds holding IBB

Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
WA
WestEnd Advisors Charlotte, North Carolina $4.49B AUM 19.44% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
AFG
Albion Financial Group Salt Lake City, Utah $1.73B AUM 20.99% 1-Year Est. Return
GIC
Generali Investments CEE Prague, Czech Republic $2.11B AUM 25.53% 1-Year Est. Return
IHL
Investment House LLC Redondo Beach, California $2.21B AUM 39.6% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $58.2B AUM 22.78% 1-Year Est. Return
AP
Appleton Partners Boston, Massachusetts $1.63B AUM 38.57% 1-Year Est. Return
FMI
Factory Mutual Insurance Waltham, Massachusetts $10.6B AUM 34.1% 1-Year Est. Return

Accredited Investors's IBB Position: Q2 2026 in Review

Accredited Investors opened a new position in iShares Biotechnology ETF (IBB) in Q2 2026: 2,426 shares worth $461K. The stake represents 0.02% of the portfolio and ranks #185 among its holdings.

421 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

  • Accredited Investors held 2,426 shares of iShares Biotechnology ETF worth $461K as of Q2 2026.
  • iShares Biotechnology ETF was a new Accredited Investors position in Q2 2026.
  • iShares Biotechnology ETF made up 0.02% of Accredited Investors's portfolio in Q2 2026, its #185 holding.
  • 421 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on Accredited Investors's 13F filing for Q2 2026, filed 21 Jul 2026.